Travaglino A, et al. - Researchers investigated the predictive value of loss of PTEN expression on pre-treatment endometrial specimen for response to progestins in endometrial hyperplasia (EH) and early endometrial cancer (EEC). Searching MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov, OVID and Cochrane Library from the inception to May 2018, they included 7 cohort studies assessing 376 patients. Outcomes of this analysis suggest no utility of PTEN as a predictive marker of response to the conservative treatment of EH and EC. The administration route (oral or intrauterine) of progestins did not influence the outcome.